Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC ...
Zacks Investment Research on MSN
Moderna (MRNA) may report negative earnings: Know the trend ahead of next week's release
The market expects Moderna (MRNA) to deliver a year-over-year increase in earnings on higher revenues when it reports results ...
By Blake Brittain April 24 (Reuters) - German biotech company CureVac sued Moderna in Delaware federal court on Friday, ...
The world’s first combination seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has received marketing ...
This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world’s ...
COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...
After more than half a century of mandatory vaccination, the U.S. military will no longer require all American troops to get ...
April 21 (Reuters) - Moderna said on Tuesday the European Commission had approved its combination vaccine for the prevention ...
Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...
A phase 3 study of Moderna’s investigational mRNA-based H5 pandemic influenza vaccine candidate has been initiated. Read more ...
The American pharmaceutical and biotechnology company Moderna has initiated a large clinical trial around a vaccine designed ...
Moderna stock gains as the company begins dosing in a Phase 3 trial designed to evaluate its messenger RNA-based bird flu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results